Rezolute (RZLT) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rezolute is the larger company by market cap ($448.8 million vs $364.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RZLT | SCTX |
|---|---|---|
| Share price | $4.64 | $19.23 |
| Market cap | $448.79M | $364.06M |
| 1-day change | +5.94% | +9.45% |
| YTD return | +96.61% | — |
| 1-year return | -46.79% | — |
| 5-year return | -30.23% | — |
| EPS (TTM) | $-0.75 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.46 | $39.60 |
| 52-week low | $1.07 | $13.50 |
| Distance from 52-week high | -59.50% | -51.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +111.21% | +196.41% |
| Average volume | 1.50M | 357.40K |
| Shares outstanding | 96.72M | 18.93M |
| Employees | 58 | 82 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Healthcare · Biotechnology · 58 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Healthcare · Biotechnology · 82 employees
RZLT vs SCTX FAQ
Which is bigger, Rezolute or Scribe Therapeutics?
Rezolute (RZLT) is larger, with a market capitalization of $448.79M compared with $364.06M for Scribe Therapeutics (SCTX).
Are Rezolute and Scribe Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.